Liang X-J.
National Center for Nanoscience and Technology of China, CN
Keywords: cisplatin, nanomaterials, tumor treatment
Chemotherapy is one of most effective cures to treat different of malignant tumors. Cisplatin is a chemotherapeutic compound commonly used in clinics, however, acquired resistance confines its application in chemotherapeutics. To overcome the acquired resistance to cisplatin, it is reasoned, based on our previous findings of certain nanoparticles-mediated cellular responses, that metallofullerene may reverse tumor resistance to cisplatin by reactivating the impaired endocytosis of cisplatin-resistant (CP-r) cells. Exposure of the CP-r tumor cells to cisplatin in the presence of metallofullerene not only decreased the number of surviving CP-r cancer cells, but also reduced the size of CP-r tumors in the xenograft mice as measured by both optical and magnetic resonance imaging (MRI). Labeling the CP-r cells with transferrin, an endocytotic marker, demonstrated that pretreatment of the CP-r cells with metallofullerene enhanced intracellular accumulation of cisplatin and formation of cisplatin-DNA adducts by restoring defective endocytotic function. It clearly demonstrated that metallofullerene nanoparticles enable a significant advance in overcoming tumor resistance to cisplatin. The technology might be extended to other challenges related to nanomaterials with unique physic-chemical characterizations employed in cancer treatments.
Journal: TechConnect Briefs
Volume: 3, Nanotechnology 2010: Bio Sensors, Instruments, Medical, Environment and Energy
Published: June 21, 2010
Pages: 420 - 423
Industry sector: Medical & Biotech
Topics: Biomaterials, Cancer Nanotechnology
ISBN: 978-1-4398-3415-2